# A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.

> **NCT00558298** · PHASE3 · COMPLETED · sponsor: **Janssen, LP** · enrollment: 811 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00558298
- **Lead sponsor:** Janssen, LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 811 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558298, "A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00558298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*